NSE: JUBLINGREA · 29 October 2026
- Jubilant Ingrevia has fallen 10.20% over 2 trading sessions; today's move is -4.34%.
- The company reported its financial results for the quarter ended September 30, 2026, posting total revenue of ₹1,394 crore, up 24% year-on-year, and an EBITDA of ₹221 crore, representing a 51% increase from the same period last year. Net profit after exceptional items reached ₹111 crore, reflecting a 61% year-on-year growth driven by solid performance across Specialty Chemicals, Nutrition, and Chemical Intermediates segments.
- Trading volume was 2.49 times the 20-day average daily volume.
Jubilant Ingrevia share price: 10.20% decline over 2 trading sessions
Jubilant Ingrevia Ltd. shares fell 4.34% on Wednesday, closing at ₹567.85 after moving within a day's range of ₹561.85 to ₹592.95.
The broader market and sector trend showed resilience on Wednesday, with the benchmark Nifty rising 1.05% and the Nifty Metal sector advancing 0.67%. Jubilant Ingrevia's downward movement ran counter to the positive broader market backdrop, extending a near-term correction that includes a 5-day return of -6.83% and a 20-day return of -11.15%.
Company disclosures from October 27, 2026, highlighted a strong financial performance for the quarter and half year ended September 30, 2026, with total quarterly revenue rising 24% year-on-year to ₹1,394 crore and EBITDA increasing 51% year-on-year to ₹221 crore. Additionally, filings noted an agreement to acquire a 40% stake in ZettaOne Technologies Limited for ₹189.2 crore to expand into the electronics and semiconductor space, though ongoing profit-taking following recent weakness appears to have weighed on the stock price.
10.82 lakh shares traded by 29 October 2026 · 03:25 PM IST. This compares with a 20-day average daily volume of 4.35 lakh shares (2.49 times). The five-day average daily volume was 10.88 lakh shares. Separately, the NSE report for 28 October 2026 showed 10.38 lakh shares delivered, representing 49.40% of that day’s traded volume. The same report recorded 70,544 trades.
The stock declined 4.34% on higher-than-average volume despite reporting strong Q2 FY27 results and an acquisition announcement, suggesting that profit-taking and broader selling pressure outweighed the positive operational updates.
Latest Company Developments
The company reported its financial results for the quarter ended September 30, 2026, posting total revenue of ₹1,394 crore, up 24% year-on-year, and an EBITDA of ₹221 crore, representing a 51% increase from the same period last year. Net profit after exceptional items reached ₹111 crore, reflecting a 61% year-on-year growth driven by solid performance across Specialty Chemicals, Nutrition, and Chemical Intermediates segments.
Quarterly earnings figures directly impact fundamental valuations and reflect the operational execution of the company's Pinnacle strategy.
Management announced an agreement to acquire a 40% stake in ZettaOne Technologies Limited with an investment of ₹189.2 crore. This move marks the company's entry into the Electronics Development and Manufacturing Services (EDMS) space, aimed at offering integrated solutions to customers in electronics and semiconductor sectors.
Strategic M&A activity expands the company's addressable market into high-growth technology and semiconductor supply chains.
The company informed exchanges that Ms. Vinita Koul, Senior Vice President and Head of HR, tendered her resignation effective from the close of business hours on November 6, 2026, to pursue other professional interests. The company noted that transition arrangements are underway to ensure operational continuity.
Senior management departures require monitoring of organizational transition, though it is typically a routine corporate update unless accompanied by broader operational disruptions.
a press release dated October 27, 2026, titled "Press Release and Presentation on the financials and operational performance of the Company for the quarter and half year ended September 30, 2026".
Grant of Stock Options under Jubilant Ingrevia Employees Stock Option Scheme 2021.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 22.59% on 30 September 2026. This compares with 22.39% on 30 June 2026, a change of +0.20 percentage points.
The filing reported 26 MF/UTI holders.
Research & Brokerage Views
Retained a 'Buy' rating on expectations of sharp earnings growth ahead, supported by strategic business execution.
Maintained a positive view citing expected earnings inflection across key chemical and nutrition segments.
Historical Bulk / Block Deals
What to Watch Next
- Execution progress and integration timeline of the ZettaOne Technologies acquisition
- Volume and delivery trends following the heavy cash participation seen on Wednesday
- Demand recovery and pricing trends in the Agrochemicals segment and Pyridine & Picolines
- Commissioning progress of the new Multi-Purpose Plant targeted by year-end
Other Dated Coverage
- Jubilant Ingrevia Share Price Falls 8.02% Intraday, Closes 6.13% Lower | 28 October 2026 — 28 October 2026
- Jubilant Ingrevia Share Price Jumps 8.65% Intraday, Closes 4.35% Higher | 27 October 2026 — 27 October 2026
More Jubilant Ingrevia news and dated analysis →
Frequently Asked Questions
What is the latest Jubilant Ingrevia company news?
The company reported its financial results for the quarter ended September 30, 2026, posting total revenue of ₹1,394 crore, up 24% year-on-year, and an EBITDA of ₹221 crore, representing a 51% increase from the same period last year. Net profit after exceptional items reached ₹111 crore, reflecting a 61% year-on-year growth driven by solid performance across Specialty Chemicals, Nutrition, and Chemical Intermediates segments.
How strong was Jubilant Ingrevia’s trading volume?
10.82 lakh shares traded, 2.49 times the 20-day average daily volume. The price and volume data are dated 29 October 2026 · 03:25 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.